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Abstract: Introduction: Many studies in stem cell biology have demonstrated that dental pulp stem
cells (DPSC) may be highly proliferative and capable of pluripotent differentiation into many different
tissue types. Recent advances in stem cell research have outlined methods for directing in vitro
or in vivo growth, viability, and proliferation, as well as differentiation of DPSC—although much
remains to be discovered. Based upon this information, the primary objective of this study was to
understand the functional biomaterials needed to more effectively direct DPSC viability, growth, and
proliferation. Methods: Using an approved protocol, previously collected and isolated samples of
DPSC from an existing repository were used. Previously established stem cell biomarkers (Sox-2,
Oct-4, NANOG) from each isolate were correlated with their proliferation rates or doubling times
to categorize them into rapid, intermediate, or slow-dividing multipotent DPSC. Growth factors
and other functional dental biomaterials were subsequently tested to evaluate DPSC responses
in proliferation, viability, and morphology. Results: Differential responses were observed among
DPSC isolates to growth factors, including vascular endothelial growth factor (VEGF) and bone
morphogenic protein (BMP-2), and functional biomaterials such as mineralized trioxide aggregates
(MTA). The responsiveness of DPSC isolates did not correlate with any single factor but rather with
a combination of proliferation rate and biomarker expression. Conclusions: These data strongly
suggest that some, but not all, DPSC isolates are capable of a robust and significant in vitro response
to differentiation stimuli, although this response is not universal. Although some biomarkers and
phenotypes that distinguish and characterize these DPSC isolates may facilitate the ability to predict
growth, viability, and differentiation potential, more research is needed to determine the other
intrinsic and extrinsic factors that may contribute to and modulate these DPSC responses to these
functional biomaterials for biotechnology and bioengineering applications.
Keywords: dental pulp; stem cell; differentiation; biotechnology; bioengineering
1. Introduction
Many studies in stem cell biology have demonstrated that dental pulp stem cells
(DPSC) may be highly proliferative and capable of pluripotent differentiation into many
different tissue types [1,2]. For example, evidence has shown that DPSC may be induced
into dentinogenesis, osteogenesis, chondrogenesis, adipogenesis, and neurogenesis [3,4].
However, much remains to be discovered regarding the materials and methods used to
stimulate growth, increase viability, and promote differentiation, as well as the biomarkers
and properties of the DPSC that determine their differentiation potential [5–7].
Recent advances in stem cell research have outlined the characteristics of DPSC that
may be useful in directing in vitro or in vivo differentiation [8,9]. For example, stem cells
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from human exfoliated deciduous teeth (SHED) and stem cells from the apical papilla
(SCAP) may express vastly different biomarkers and differentiation potentials [10,11]. More-
over, the methods used to isolate and store these DPSC may also influence the capacity and
potential of these DPSC isolates for any therapeutic or bioengineering purposes [12,13].
For example, some studies have revealed that the isolation of DPSC using enzymatic
dissociation may result in heterogenous DPSC isolate populations of more rapidly dividing
cells, while the direct outgrowth technique from tissue explants may be more likely to
give rise to more homogenous isolates with more limited differentiation potential [14,15].
In addition to the isolation methods used, the protocols and techniques used in cryop-
reservation may also influence the potential viability and long-term survival following
cryopreservation—with research studies suggesting that both lower passage number and
decreased concentration of dimethyl sulfoxide (DMSO) may significantly improve both
survival and viability outcomes among DPSC isolates [13,15].
Other research has outlined potential methods used to direct in vitro or in vivo dif-
ferentiation [16,17]. Some of these efforts have involved the use of defined growth factors
and growth media supplements, including the use of transforming growth factor (TGF),
platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and nerve growth
factor (NGF) to induce DPSC differentiation [18–20]. However, the most commonly cited
and effective growth factors added to cell culture media that appear to modulate differenti-
ation across many types of DPSC include bone morphogenic protein (BMP) and vascular
endothelial growth factor (VEGF)—which have been demonstrated to increase proliferation
as well as viability in these studies [16–20]. Other researchers have explored the potential
bioactivity of dental materials, such as endodontic biomaterials including mineralized
trioxide aggregates (MTA) on DPSC [21–23]. However, the vast majority of these studies
to date have not included an extensive characterization of these DPSC isolates, including
proliferation rate or doubling time, biomarker expression, and analysis of pluripotent
differentiation markers—which may, in fact, be critical to understanding which factors may
modulate specific responses among differing DPSC isolates to induce differentiation.
Based upon this information, the primary objective of this study was to understand the
biology and biotechnology needed to more effectively modulate DPSC phenotypes, includ-




Previously collected and isolated samples of DPSC from an existing repository were
used. Due to the use of previously collected, non-identifiable samples, this protocol
was granted exemption from Human Subjects review from the University of Nevada,
Las Vegas (UNLV) Office for the Protection of Research Subjects (OPRS) #763012-1 titled
“Retrospective analysis of dental pulp stem cells (DPSC) from the University of Nevada,
Las Vegas (UNLV) School of Dental Medicine (SDM) pediatric and clinical population” on
3 August 2015.
The original protocol for the collection and storage of DPSC was reviewed and ap-
proved by the Institutional Review Board (IRB) and UNLV OPRS under OPRS#0907-3148
“Isolation of Non-Embryonic Stem Cells from Dental Pulp” [24] on 5 February 2010.
2.2. Cell Culture
DPSC isolates frozen in 10% dimethyl sulfoxide (DMSO)-containing media were
thawed and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) High Glucose with
the addition of 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin strepto-
mycin (Pen-Strep) at 37 ◦C in a humidified tissue culture incubator with 5% CO2. DMSO
(CAS 67-68-5), DMEM (MT15017CV), FBS (MT35011CV), and Pen-Strep (MT30001Cl) were
obtained from Fisher Scientific (Fair Lawn, NJ, USA). Cells were passaged 1:2 and doubling
time was noted for each DPSC isolate. Cell cultures achieving confluence within 1–2 days
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were categorized as rapid doubling time or rDT between 1 and 2 days, with intermedi-
ate doubling time or iDT noted between 5 and 6 days, and slow doubling time or sDT
categorized as 10–12 days.
2.3. RNA Isolation
RNA was isolated from each DPSC using the ABgene Total RNA isolation reagent kit
and protocol recommended by ThermoFisher (Fisher Scientific; Fair Lawn, NJ, USA), as
previously described [24,25]. All samples were screened for purity using the NanoDrop
spectrophotometer (Fisher Scientific; Fair Lawn, NJ, USA) absorbance readings at A260
and A280 nm. The ratio of A260:A280 provides an approximation of nucleic acid purity.
All samples were required to demonstrate an A260:A280 ratio above 1.65, which was
suitable for polymerase chain reaction (PCR) screening. Quantification of RNA samples
was concomitantly collected to determine the minimal PCR processing requirement of
1 ng/µL.
2.4. PCR Screening
RNA obtained from each DPSC isolate was subsequently screened for the presence
of CD90 and CD105 and the absence of CD45, according to the International Society for
Cellular Therapy (ISCT) criteria for stem cells [26] using RT-PCR on 1 ug of total RNA
with the ABgene Reverse-iT One-Step RT-PCR kit (ThermoFisher Scientific; Fair Lawn, NJ)
and a Mastercycler gradient thermocycler (Eppendorf; Hamburg, Germany) that included
an initial reverse transcription at 47 ◦C for 30 min, followed by 30, cycles of PCR with
annealing for 30 sec at the appropriate temperature for each primer set, and final extension
at 60 ◦C for one minute, as previously described [24–26]. The PCR positive cellular RNA
control was glyceraldehyde 3-phosphate dehydrogenase (GAPDH). In addition, three
additional mesenchymal stem cell (MSC) markers (Sox-2, Oct-4, and NANOG) were also
used with the following primers, synthesized by SeqWright (Fisher Scientific; Fair Lawn,
NJ, USA).
CD90 forward: 5′-ATGAACCTGGCCATCAGCA-3′; 19 nt, 53% GC, Tm: 67 ◦C
CD90 reverse: 5′-GTGTGCTCAGGCACCCC-3′; 17 nt, 71% GC, Tm: 70 ◦C
Optimal Tm: 68 ◦C
CD105 forward: 5′-CCACTAGCCAGGTCTCGAAG-3′; 20 nt, 60% GC, Tm: 67 ◦C
CD105 reverse: 5′-GATGCAGGAAGACACTGCTG-3′; 20 nt, 55% GC, Tm: 66 ◦C
Optimal Tm: 67 ◦C
CD45 forward: 5′CATATTTATTTTGTCCTTCTCCCA-3′; 24 nt, 33% GC, Tm: 60 ◦C
CD45 reverse: 5′-GAAAGTTTCCACGAACGG-3′; 18 nt, 50% GC, Tm: 61 ◦C
Optimal Tm: 61 ◦C
Oct-4 forward: 5′-TGGAGAAGGAGAAGCTGGAGCAAAA-3′; 25 nt: 48% GC; Tm
70 ◦C Oct4 reverse: 5′-GGCAGATGGTCGTTTGGCTGAATA-3′; 24 nt; 50% GC; Tm 70 ◦C
Optimal Tm: 71 ◦C
Sox2 forward: 5′-ATGGGCTCTGTGGTCAAGTC-3′; 20 nt: 55% GC; Tm 67 ◦C
Sox2 reverse: 5′-CCCTCCCAATTCCCTTGTAT-5′; 20 nt; 50% GC; Tm 64 ◦C
Optimal Tm: 65 ◦C
NANOG forward: 5′-GCTGAGATGCCTCACACGGAG-3′; 21 nt; 62% GC; Tm 71 ◦C
NANOG reverse: 5′-TCTGTTTCTTGACTGGGACCTTGTC-3′; 25 nt: 48%GC; Tm
69 ◦C Optimal Tm: 70 ◦C
GAPDH forward: 5′ATCTTCCAGGAGCGAGATCC-3′; 20 nt, 55% GC, Tm 66 ◦C
GAPDH reverse: 5′ACCACTGACACGTTGGCAGT-3′; 20 nt, 55% GC, Tm 70 ◦C
Optimal Tm: 61 ◦C
2.5. Proliferation Assays
DPSC isolates were plated in sterile, tissue culture-treated Corning Costar 96-well
assay plates (Fisher Scientific 07-200-90; Fair Lawn, NJ, USA) at a concentration of 1.2× 104
cells/mL for three days. Experimental wells were treated with either 10 ng/mL of Gibco
J. Funct. Biomater. 2021, 12, 15 4 of 12
with recombinant vascular endothelial growth factor (VEGF, ThermoFisher #PHC9393;
Fair Lawn, NJ, USA) or bone morphogenic protein (BMP-2, ThermoFisher #PHC7141;
Fair Lawn, NJ, USA) or plated with 10 ug of MTA (Henry Schein #7040069; Melville, NY,
USA). Plates were subsequently fixed with 10% neutral buffered formalin (ThermoScientific
22-045-400; Fair Lawn, NJ, USA) and stained using Gentian Violet 1% aqueous solution
(Ricca Chemical 7647-01-0 from Fisher Scientific; Fair Lawn, NJ, USA). Absorbance was
read using an ELx808 BioTek microplate reader (BioTek; Winooski, VT, USA) at 595 nm to
calculate cellular proliferation and for comparison with negative controls.
2.6. Viability Assays
Cellular viability was determined using the Trypan Blue exclusion assay from Gibco
(Fisher Scientific #15250061; Fair Lawn, NJ, USA). Cells (experimental, control) were
processed using a BioRad TC20 automated cell counter (BioRad; Hercules, CA, USA) to
determine the absolute and relative percentage of viable cells. Cell densities were also
calculated for both experimental and negative controls.
2.7. Experimental Factors
Growth factors were obtained from Fisher Scientific, which included vascular en-
dothelial growth factor (VEGF; catalog PHC9393) and bone morphogenic protein (BMP;
catalog PHC7141). Experimental wells were treated with growth factor (VEGF or BMP-2)
at physiologically relevant concentrations approximating 10 ng/mL—within the range of
other studies of DPSC responsiveness to these growth factors [27–30]. Mineralized trioxide
aggregate (MTA) was obtained from Henry Schein (catalog 7040069). In brief, MTA was
mixed separately under sterile conditions in a BSL-2 biosafety cabinet according to the
manufacturer instructions and 10 µL was transferred into each experimental well of a
96-well assay plate prior to cell plating (as described above).
2.8. Statistical Analysis
All parametric analyses of growth and viability were exported to Microsoft Excel (XLS)
and subsequently analyzed using two-tailed t-tests. Statistical differences were calculated
using an alpha level of 0.05 for statistical significance, as previously described [30,31].
Differences in RNA concentration were calculated based upon the doubling time (DT) or
group, which are non-parametric or categorical groups, as previously described [28–32].
These data were analyzed using the Chi square test. Associations were estimated between
growth or viability responsiveness (change) and DPSC categorical variables (rDT, iDT, sDT)
using Pearson’s correlation coefficient or R2, as previously described [24–26,31,32].
3. Results
Existing DPSC isolates were thawed and placed into culture with the average doubling
time (DT) noted for each (Figure 1). These data demonstrated that two DPSC isolates ex-
hibited a rapid and consistent doubling time or rDT of approximately two days (dpsc-3882,
dpsc-5653). In addition, two DPSC isolates were identified as exhibiting an intermediate
doubling time or iDT of approximately five to six days (dpsc-8124, dpsc-9894). Finally, two
DPSC isolated were found to have slow doubling times or sDT between ten to twelve days
(dpsc-11418, dpsc-11750). The average doubling times for each grouping (rDT, iDT, and
sDT) were significantly different from each other, p = 0.0001.




Figure 1. Cell culture reveals dental pulp stem cell (DPSC) doubling time (DT). Average doubling time for DPSC isolates 
was categorized as rapid or rDT (1–2 days; dpsc-3882, dpsc-5653), intermediate or iDT (5–6 days; dpsc-8124, dpsc-9894), 
or slow sDT (10–12 days; dpsc-11418, dpsc-11750), which remained consistent and were significantly different from one 
another, p = 0.0001. 
RNA was subsequently extracted from each DPSC isolate and prepared for analysis 
(Table 1). These data revealed the average RNA concentration for all DPSC isolates was 
approximately 906 ng/μL. The average RNA concentration for the rDT DPSC isolates was 
904.2 ng/μL, while the average RNA concentration for the iDT and sDT DPSC isolates was 
904.2 and 919.4 ng/μL, respectively. These data revealed that no significant differences 
were observed between these groups, p = 0.325. The purity of the RNA was determined 
using the ratio of spectrophotometer absorbance readings at A260 and A280 nm, which 
revealed that average A260:A280 ratios for all DPSC isolates exceeded 1.65—the minimum 
acceptable standard for polymerase chain reaction (PCR) screening. 
Table 1. RNA concentration from DPSC isolates. 
DPSC Isolate RNA Quantification Statistical Analysis RNA Purity 
dpsc-3882 921.1 ng/μL – 1.74 
dpsc-5653 887.3 ng/μL – 1.77 
dpsc-8124 925.6 ng/μL – 1.72 
dpsc-9894 913.2 ng/μL – 1.65 
dpsc-11418 879.4 ng/μL – 1.91 
dpsc-11750 910.1 ng/μL – 1.83 
rDT 904.2 ng/μL X2 = 0.325 ave. = 1.75 
iDT 919.4 ng/μL d.f. = 2 ave. = 1.69 
sDT 894.75 ng/μL p = 0.8502 ave. = 1.87 
Screening of the RNA from each DPSC isolate for the ICST biomarkers, including 
CD45, CD90, and CD105, was performed (Figure 2). These data demonstrated that all 
DPSC isolates expressed both CD90 and CD105, but did not express CD45. In addition, 
the RNA was also screened for three additional mesenchymal stem cell pluripotency bi-
omarkers, including Sox-2, Oct-4, and NANOG. These data revealed that both rapidly 
dividing DPSC isolates (rDT), dpsc-3882 and dpsc-5653, expressed all three biomarkers. 
The intermediate doubling time DPSC isolates (iDT), dpsc-8124 and dpsc-9894, both ex-
pressed NANOG but exhibited differential expression of Sox-2 and Oct-4. Finally, neither 
of the slow doubling time DPSC isolates (sDT) expressed Sox-2 or Oct-4 and only dpsc-
11418 exhibited measurable NANOG expression. 
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DPSC isolates expressed both CD90 and CD105, but did not express CD45. In addition,
the RNA wa also screened for three additional mesenchymal stem cell pluripotency
biomarkers, inc uding Sox-2, Oct-4, an NANOG. These dat revealed that both rapidly
dividing DPSC isolates (rDT), dpsc-3882 and dpsc-5653, expressed all three biomarkers. The
intermediate doubling time DPSC isolates (iDT), dpsc-8124 and dpsc-9894, both expressed
NANOG but exhibited differential expression of Sox-2 and Oct-4. Finally, neither of the
slow doubling time DPSC isolates (sDT) expressed Sox-2 or Oct-4 and only dpsc-11418
exhibited meas rable NANOG expression.




Figure 2. Results of DPSC isolate PCR biomarker screening. Positive results for CD90 and CD105 RNA expression were 
observed among all DPSC isolates, with negative results for CD45 expression. Differential results were observed among 
the DPSC isolates for Sox-2, Oct-4, and NANOG expression. Only the rDT (rapid) DPSC isolates expressed all three plu-
ripotency biomarkers, with differential expression observed among the iDT and sDT DPSC isolates. Note:  indicates 
RT-PCR band intensity above the limit of detection;  indicates an RT-PCR result below the limit of detection. 
To determine the effects of VEGF on these DPSC isolates, all cells were plated with 
(experimental) and without (negative) VEGF at a concentration of 10 ng/mL—a physio-
logically relevant concentration used in other experimental protocols involving DPSC 
(Figure 3). These data demonstrated significant increases in cellular viability and prolifer-
ation among the rDT DPSC isolates (dpsc-3882: 22.1%, 34.2%, respectively; dpsc-5653: 
26.3%, 32.1%, respectively), p = 0.0001. Although more moderate increases in both viability 
and growth were observed among the iDT DPSC isolates (dpsc-8124: 13.2%, 7.6%, respec-
tively; dpsc-9894: 12.4%, 9.9%, respectively), these were significantly different from the 
negative (untreated) controls, p = 0.002. However, no significant differences in viability or 
growth were observed among the sDT DPSC isolates (dpsc-11418: 2.4%, 1.6%, respec-
tively; dpsc-11750: 1.9%, 2.1%, respectively), p = 0.441.  
 
Figure 3. Effect of vascular endothelial growth factor (VEGF) on DPSC isolates. VEGF induced 
marked increases in viability and growth among the rDT (rapid) DPSC isolates (dpsc-3882, dpsc-
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To determine the effects of BMP-2 on these DPSC isolates, all cells were plated with
(experimental) and without (negative) BMP-2 at a concentration of 10 ng/mL—a physi-
ologically relevant concentration used in other experimental protocols involving DPSC
(Figure 4). These results revealed no significant changes in either cellular viability or
proliferation from the untreated controls among the rDT DPSC isolates (dpsc-3882: 1.2%,
2.4%, respectively; dpsc-5653: 2.2%, 3.1%, respectively), p = 0.541. Slight increases in both
viability and growth were observed among the iDT DPSC isolates (dpsc-8124: 3.5%, 2.2%,
respectively; dpsc-9894: 2.6%, 3.4%, respectively), although these were not significantly
different from the negative (untreated) controls, p = 0.0811. However, significant differences
in viability or growth were observed among the sDT DPSC isolates (dpsc-11418: 31.6%,
29.1%, respectively; dpsc-11750: 25.6%, 19.8%, respectively), p = 0.0001.
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material (Figure 5). A strong negative effect was observed between MTA administration
and both the growth and viability of the rDT DPSC isolates (dpsc-3882: −15.2%, −13.9%,
respectively; dpsc-5653: −9.1%, −18.4%, respectively), p = 0.003. A more moderate but
still negative effect was observed among the iDT DPSC isolates (dpc-8124: −2.5%, −4.2%,
respectively; dpsc-9894: −1.3%, −6.1%, respectively), p = 0.064. However, a significant
positive effect was observed in viability and growth among the sDT DPSC isolates (dpsc-
11418: 23.7%, 17.5%, respectively; dpsc-11750: 28.3%, 36.2%, respectively), p = 0.0001.
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( ntermediate) DPSC isolates (dpsc-8124, dpsc-9894) but to a lesser extent, p = 0.064. However, MTA indu ed significant
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The responsivene s of the DPSC to each of the thr e experimental treatments, includ-
ing the percentage change in growth and viability, was summarized (Table 2). These data
demonstrated t at t responsivenes to VEGF was observed among the rDT and iDT
PSC isolates, which correlated with the ICST and MSC biomarkers. For exampl , the rDT
DPSC isolates (dpsc-3882, dpsc-5653) expressed all three MSC biomarkers (Sox-2, Oct-4,
NANOG) and were the most responsive to VEGF administration. The iD DPSC isolates
expressing only two of the three MSC biomarkers (dpsc-8124; Sox-2, NANOG; dpsc-9894;
Oct-4, NANOG) were less responsive to VEGF than either of the rDT DPSC isolates.
These correlations also suggested correlations with DPSC responses to MTA, which
more strongly inhibited growth in proliferation among the rDT DPSC isolates (expressing
all three MSC biomarkers) than the iDT DPSC isolates (expressing two MSC biomarkers).
Interestingly, only the sDT DPSC isolates expressing one (NANOG) or none of the MSC
pluripotency biomarkers exhibited positive responsiveness to MTA treatment. Similarly,
the only group of DPSC isolates exhibiting responsiveness to BMP-2 treatment were the
sDT DPSC isolates—which may suggest that the presence of two or more of the MSC
pluripotency markers may be sufficient to inhibit DPSC responsiveness.
To evaluate the association between the responsiveness of DPSC isolates (either growth
or viability) and DPSC category (rDT, iDT, sDT), Pearson’s correlation was performed,
which demonstrated strong associations may exist. For example, the association between
DPSC isolate responsiveness in viability to VEGF administration was R2 = 0.868, while
the association between responsiveness in growth to VEGF was R2 = 0.82. Similarly, the
responsiveness in viability and growth of the DPSC isolates by category to BMP-2 was
R2 = 0.667 and R2 = 0.588, respectively. Finally, the correlations between MTA and DPSC
responsiveness were R2 = 0.904, R2 = 0.831.
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Table 2. Responsiveness of DPSC isolates to stimulus.





dpsc-3882 22.1%, 34.2% 1.2%, 2.4% −15.2%, −13.9%
dpsc-5653 26.3%, 32.1% 2.2%, 3.1% −9.1%, −18.4%
dpsc-8124 13.2%, 7.6% 3.5%, 2.2% −2.5%, −4.2%
dpsc-9894 12.4%, 9.9% 2.6%, 3.4% −1.3%, −6.1%
dpsc-11418 2.4%, 1.6% 31.6%, 29.1% 23.7%, 17.5%
dpsc-11750 1.9%, 2.1% 25.6%, 19.8% 28.3%, 36.2%
rDT ++, +++ +, + −−, −−
iDT ++, + +, + −, −
sDT +, + ++, ++ ++, ++
Correlation (R2) R2 = 0.868, R2 = 0.82 R2 = 0.667, R2 = 0.588 R2 = 0.904, R2 = 0.831
4. Discussion
The primary objective of this study was to understand the biology and biotechnology
needed to more effectively modulate DPSC responsiveness and phenotypes, using BMP,
VEGF, and MTA. The results of this study have demonstrated that specific biological
determinants of DPSC pluripotency, including Sox-2, Oct-4, and NANOG, may be effective
biomarkers to determine the responsiveness of DPSC isolates to various stimuli—at least
in vitro [31,32]. These results support other studies of DPSC characteristics and biomarkers
that evaluate the potential for reprogramming and differentiation [33,34].
In addition, these data also confirm previous studies of DPSC responsiveness to
various growth factors, including VEGF and BMP-2 [18–20,35,36]. One of these previous
studies evaluated the pluripotency transcription factors Sox-2 and Klf-4, but did not
evaluate the potential responsiveness of DPSC isolates to any stimulus or growth factors
based upon expression of these markers [33]. However, this study may be among the first
to demonstrate the differential responsiveness of DPSC to these growth factors based upon
the combination of these specific pluripotency biomarkers (Sox-2, Oct-4, NANOG) and
growth characteristics, such as doubling time or proliferation.
Studies from other groups have identified similar biomarkers among DPSC that may
be used to determine functional differentiation capabilities, such as the expression of Oct-4,
Sox-2, and Klf-4 with Lin28, which may determine DPSC isolates capable of odontoblastic
differentiation [37]. Other research groups have focused on the identification of additional
growth factors that may promote specific and directed differentiation of DPSC isolates,
such as basic fibroblast growth factor (bFGF) promotion of DPSC neural differentiation and
fibroblast growth factor (FGF-2) promotion of DPSC odontoblast differentiation [38,39].
Although the results of this study are novel and suggest effective methods for evaluat-
ing and selecting differentiation potential among DPSC isolates, there are several limitations
associated with this study that must be considered. For example, any association between
the expression of these biomarkers and DPSC responsiveness may be coincidental and
not causative. The retrospective nature of this study, combined with both financial and
technical barriers that limited the ability of this group to evaluate this possibility through
knockout or silencing RNA, suggest that future studies may need to include methods to
rule out these possibilities.
In addition, this study was limited to a small number of DPSC isolates. Expanding
this study to include more DPSC isolates with variable expression of these pluripotency
biomarkers will provide substantial information that could validate the findings of the
current study. In addition, a more comprehensive evaluation of other potential biomarkers,
such as non-coding microRNA, may provide more specific and targeted methods for
bioengineering and biotechnology applications utilizing DPSC [40–42].
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5. Conclusions
These data suggest that some DPSC isolates (but not all) are capable of a robust and
significant in vitro response to stimuli, although this response is not universal. Although
some biomarkers and phenotypes that distinguish and characterize these DPSC isolates
may facilitate the ability to predict phenotypic responses and changes in growth or vi-
ability potential, more research is needed to determine the other intrinsic and extrinsic
factors that may contribute to and modulate these DPSC responses for biotechnology and
bioengineering applications.
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Abbreviations
Abbreviation Name
DPSC Dental pulp stem cell
VEGF vascular endothelial growth factor
BMP bone morphogenic protein
MTA mineralized trioxide aggregates
SHED stem cells from human exfoliated deciduous teeth
SCAP stem cells from the apical papilla
UNLV University of Nevada, Las Vegas
OPRS Office for the Protection of Research Subjects
SDM School of Dental Medicine
DMSO dimethyl sulfoxide
DMEM Dulbecco’s Modified Eagle’s Medium
FBS fetal bovine serum
rDT rapid doubling time
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iDT intermediate doubling time
sDT slow doubling time
PCR polymerase chain reaction
ISCT International Society for Cellular Therapy
MSC mesenchymal stem cell
GAPDH glyceraldehyde 3-phosphate dehydrogenase
bFGF basic fibroblast growth factor
FGF fibroblast growth factor
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